ASP Isotopes Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
2024年7月15日 - 10:15PM
ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”)
today announced the closing of the previously announced
underwritten public offering of shares of its common stock. ASP
Isotopes sold 13,800,000 shares of its common stock, which reflects
the exercise in full by the underwriter of its option to purchase
up to 1,800,000 additional shares of common stock, at a public
offering price of $2.50 per share, less underwriting discounts and
commissions. The total gross proceeds to ASP Isotopes
from the offering (before deducting the underwriting discounts and
commissions and offering expenses) were $34.5 million.
Canaccord Genuity acted as sole bookrunner for the offering.
A shelf registration statement on Form S-3 relating to
these securities has been filed with the Securities and Exchange
Commission (SEC) and has been declared effective by the SEC. This
offering was made only by means of a prospectus and a related
prospectus supplement. Copies of the final prospectus supplement,
dated July 12, 2024, and the accompanying prospectus, dated June
12, 2024, relating to the offering have been filed with the SEC and
made available on the SEC’s website at www.sec.gov. Copies of the
final prospectus supplement and the accompanying prospectus
relating to the offering may also be obtained by contacting
Canaccord Genuity LLC, Attention: Syndication Department, 1 Post
Office Square, 30th Floor, Boston, MA 02109, or by email at
prospectus@cgf.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About ASP Isotopes
ASP Isotopes Inc. is a development stage advanced materials
company dedicated to the development of technology and processes to
produce isotopes for use in multiple industries. The Company
employs proprietary technology, the Aerodynamic Separation Process
(“ASP technology”). The Company’s initial focus is on producing and
commercializing highly enriched isotopes for the healthcare and
technology industries. The Company also plans to enrich isotopes
for the nuclear energy sector using Quantum Enrichment technology
that the Company is developing. The Company has isotope enrichment
facilities in Pretoria, South Africa, dedicated to the enrichment
of isotopes of elements with a low atomic mass (light
isotopes).
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. The words “anticipate,”
“believe,” “continue,” “could,” “estimate,” “expect,” “intend,”
“hope,” “may,” “plan,” “possible,” “potential,” “predict,”
“project,” “should,” “target,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from current expectations and beliefs, including, but
not limited to: the impact of general economic, industry or
political conditions in the United States or internationally and
other important risk factors set forth under the caption “Risk
Factors” in the preliminary prospectus relating to the offering,
ASP Isotopes’ Annual Report on Form 10-K for the year ended
December 31, 2023, and in any other subsequent filings made
with the SEC by ASP Isotopes. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and ASP Isotopes specifically disclaims any obligation to update
any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
Contacts
Jason Assad– Investor relationsEmail:
Jassad@aspisotopes.com Telephone: 561-709-3043
ASP Isotopes (NASDAQ:ASPI)
過去 株価チャート
から 7 2024 まで 8 2024
ASP Isotopes (NASDAQ:ASPI)
過去 株価チャート
から 8 2023 まで 8 2024